1. Home
  2. LDI vs INDP Comparison

LDI vs INDP Comparison

Compare LDI & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$0.60

Market Cap

542.4M

Sector

Finance

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.86

Market Cap

438.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
INDP
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
542.4M
438.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
LDI
INDP
Price
$0.60
$2.86
Analyst Decision
Sell
Analyst Count
3
0
Target Price
★ $3.00
N/A
AVG Volume (30 Days)
★ 6.6M
1.4M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$17.58
N/A
Revenue Next Year
$13.99
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.92
52 Week High
$3.80
$5.96

Technical Indicators

Market Signals
Indicator
LDI
INDP
Relative Strength Index (RSI) 27.81 51.54
Support Level N/A $2.41
Resistance Level $1.19 $3.03
Average True Range (ATR) 0.06 0.62
MACD -0.01 -0.01
Stochastic Oscillator 3.53 39.33

Price Performance

Historical Comparison
LDI
INDP

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: